Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-049067
Filing Date
2024-04-26
Accepted
2024-04-26 16:01:08
Documents
11
Period of Report
2024-06-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A eypt_def_14a_04-26-2024.htm DEF 14A 1668078
2 GRAPHIC img83600834_0.jpg GRAPHIC 31402
3 GRAPHIC img83600834_1.jpg GRAPHIC 6484
4 GRAPHIC img83600834_2.jpg GRAPHIC 3687
5 GRAPHIC img83600834_3.jpg GRAPHIC 31402
6 GRAPHIC img83600834_4.jpg GRAPHIC 17608
7 GRAPHIC img83600834_5.jpg GRAPHIC 31402
8 GRAPHIC img83600834_6.jpg GRAPHIC 234957
9 GRAPHIC img83600834_7.jpg GRAPHIC 242942
10 GRAPHIC img83600834_8.jpg GRAPHIC 178870
11 GRAPHIC img83600834_9.jpg GRAPHIC 139971
  Complete submission text file 0000950170-24-049067.txt   2933932
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-51122 | Film No.: 24883374
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)